Search

Citatuzumab Bogatox

VB6-845 has demonstrated effective cancer cell killing properties in pre-clinical tests.

OM85

OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.

MG98

MG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.

Ulimorelin

Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility

ABX1100

ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.

Actelion-1

Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

Talbutal

Talbutal is a schedule III drug in the U.S.

Lestaurtinib

Zandatrigine

Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).

Indoprofen

Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.